North America Monoclonal Antibody Therapy Market

North America Monoclonal Antibody Therapy Market Size (2023 to 2028)

The North America monoclonal antibody therapy market was worth USD 65.22 Billion in 2023 and is estimated to be growing at a CAGR of 15.61%, to reach USD 134.71 Billion by 2028.

Monoclonal antibodies (mAbs), a type of monospecific antibody (protective body inflammatory response), are made up of identical antibody molecules and are produced by a single cell clone or cell line.

One of the primary factors driving the growth of the North America monoclonal antibody therapy market is the increasing prevalence of chronic disorders such as cancer. Chronic diseases are a big burden in the region, leading the government to take measures to reduce the costs associated with their spread. According to the Centers for Disease Control and Prevention, six out of every ten persons in the United States have a chronic disease, resulting in a $ 3.5 trillion yearly healthcare cost.

In addition, unmet patient demands and improved health reimbursement policies for therapeutic monoclonal antibodies utilized as a treatment option for chronic diseases are expected to drive the North America monoclonal antibody therapy market forward.

The large-scale manufacture of mAbs stimulates pharmaceutical companies to develop their own product lines for personalized medicinal products is expected to expand the market growth.

The homogeneity of mAbs also makes them appropriate for experimental methods, as it makes producing similar antibodies easier. As a result, their demand in the healthcare sector is growing.

On the other hand, the increased patient and clinician knowledge of mAb therapy, the introduction of superior products, rising antibody adoption in sensitive markets, and speedy regulatory approval for new monoclonal antibodies therapy are all aspects that are positively impacting the market.

The market for cost-effective biosimilar monoclonal antibody therapy in North America has risen significantly as a result of the increased availability of cost-effective biosimilar monoclonal antibody therapy.

Despite the positive results of monoclonal antibodies in the treatment of numerous diseases, the lengthy and stringent approval and launch procedures will be a big impediment to monoclonal antibody therapy income. In addition, many clinical studies are halted due to a failure to meet the regulatory bodies demanding standards and end findings. Other issues limiting the monoclonal antibody therapy market growth include the drug's potential negative effects.

This research report on the North America monoclonal antibody therapy  market has been segmented and sub-segmented into the following categories:

By Type:

• Human mAb
• Humanized mAb
• Chimeric mAb
• Murine mAb

By Application:

• Cancer
• Autoimmune Diseases

By Distribution Channel:

• Hospital Pharmacy Retail Pharmacy
• Online Pharmacy

By Country:

• United States
• Canada
• Rest of North America

North America dominated the monoclonal antibody therapy market. The regional market growth is attributed to the availability of well-established healthcare infrastructure, the government emphasis on infection control and management, and a higher frequency of lifestyle-related disorders. The countries such as The United States and Canada are expanding the North America monoclonal antibody therapy market.

The United States is likely to dominate the market in North America. Market growth is being driven by the rapidly increasing number of cancers, increased government investment for cancer research, and technological development. For example, the United States National Institute of Standards and Technology bio-fabrication initiative provides scientifically sound regulatory guidance to ensure the efficient and safe manufacture of protein therapies and assist biopharmaceutical manufacturers in delivering high-quality protein drugs at low costs around the world. According to the American Cancer Society forecasts for the year 2020 in the United States, there would be around 1,855,950 new cancer cases and 606,550 cancer deaths, fuel market demand.

The monoclonal antibody therapy market in Canada is expected to contribute to regional market growth in North America. 

KEY MARKET PLAYERS:

Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., CASI Pharmaceuticals, Eli Lilly and Co., Merck & Co., Inc., Changchun Zhongyingfeng Science And Technology Co., Ltd, Hangzhou Immuno Biotech Co. Ltd, Nantong Egens Biotechnology Co. Ltd are some of the dominating companies in the North America monoclonal antibody therapy market.